Aligos Therapeutics Appoints James Hassard As Executive VP And Chief Commercial Officer To Strengthen Senior Leadership

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for liver and viral diseases, announced the appointment of James Hassard, MBA, as Executive Vice President and Chief Commercial Officer, effective immediately. In this role, Hassard will lead the company’s global commercial operations and serve on Aligos’ Senior Leadership Team, helping to prepare the organization for future product launches. He brings extensive experience in building commercial organizations across multiple therapeutic areas.

Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos, stated that the company is preparing for the next stages of development of pevifoscorvir sodium through the Phase 2 B-SUPREME study. He emphasized that Hassard’s appointment strengthens Aligos’ commercial readiness as the company approaches late-stage development, moving closer to its goal of delivering improved outcomes for patients with unmet medical needs.

Hassard expressed enthusiasm about joining Aligos, noting the potential of next-generation therapies for chronic hepatitis B virus infections. He highlighted his commitment to building the global commercial infrastructure necessary to position pevifoscorvir sodium for future success and to bring better treatment options to patients.

Before joining Aligos, Hassard served as Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals, where he developed commercial strategies and launch plans for more than four rare disease programs. Earlier in his career, he held positions at Coherus Oncology, Amgen, and Merck, contributing to the launch of multiple pharmaceutical products in areas such as hepatitis, oncology, and nephrology. 

He has also held global leadership roles, including serving as General Manager of Amgen Portugal, gaining experience in the United States, Canada, and Europe. Hassard holds a Bachelor of Science in Pharmacology from the University of Toronto and a Master of Business Administration from Nova Southeastern University.